DLX-105

DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research[1].

12352203

IFNAR; Interleukin Related; TNF Receptor

Apoptosis; Immunology/Inflammation

COVID-19-immunoregulation

Inflammation/Immunology

[DLX-105]

[1]Tsianakas A, et al. The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis. Exp Dermatol. 2016 Jun;25 (6) :428-33.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991408/

Inhibitory Antibodies

No Development Reported